IMPAQTT

IMPAQTT is an independent foundation that contributes substantially to lifesaving new cancer therapies. The focus is on the new treatment options, the so-called targeted therapies. The IMPAQTT Foundation, founded in 2012 as TARGET-RCI, operates as a partner in the management of cancer treatment-associated side effects. 

The IMPAQTT Foundation is CancerMed’s Side Effects Research & Valorisation Foundation. CancerMed Side Effects Institute operates as a partner in the management of cancer treatment-associated side effects. While CancerMed Side Effects Institute focuses on the education and certification of health care professionals, the IMPAQTT Foundation focuses on research and valorisation. 

• The primary objective of the IMPAQTT Foundation is to conduct leading research on targeted anticancer therapy-associated side effects assessing frequency and severity, and their prevention and management in order to bring cancer treatment to a higher level.

• The secondary objective of the IMPAQTT Foundation is to develop and disseminate widely best evidence for prevention and management of targeted anticancer therapy-associated side effects as well as to expand their availability and use in daily practice in order to encourage full-dose-on-time treatment. 

• We want to spread the word and conduct more research.
• We are training as many doctors, nurses, and patients as possible around the world.
• We have built up a global network of oncologists, nurses, and scientists - all experts in their respective field – from Australia, Belgium, Brazil, China, Cyprus, Denmark, France, Germany, Greece, Italy, Oman, Singapore, South Africa, The Netherlands, Turkey, USA, and many more.